#Japan #Tokyo #Astellas #Audax #DAX-044

Astellas Pharma and Audax Biosciences: A New Dawn in Immuno-Oncology

In a groundbreaking development in the world of cancer treatment, Astellas Pharma Inc. and Audax Biosciences Pty Ltd have signed an exclusive option and license agreement for DAX-044, a state-of-the-art immune-targeted IL-12 antibody-cytokine fusion. This collaboration is not only set to accelerate the innovation pipeline in immuno-oncology but could also bring significant advancements to patients battling solid tumors.

Overview of the Agreement

Announced publicly on October 27, 2026, the exclusive agreement allows Astellas an option to obtain a worldwide license to develop and commercialize DAX-044. Moreover, it grants Audax the opportunity to co-fund and co-promote the product in Australia and New Zealand—demonstrating the collaborative spirit of both companies in tackling cancer head-on. The potential transaction value is estimated to reach up to $1.34 billion, excluding any royalties, marking a significant investment into cancer therapeutics.

Takahiko Iwaya, Astellas' Chief Strategy Officer, emphasized that this partnership reinforces their commitment to addressing unmet medical needs in oncology. He stated, "DAX-044 represents a promising investigational immuno-oncology program, designed to selectively activate anti-tumor immune responses. By merging Audax’s innovative approach with our extensive expertise in development and commercialization, we aspire to unveil a new treatment alternative for patients facing solid tumors."

What is DAX-044?

DAX-044 stands out as an investigational therapy harnessing the immune-activating power of interleukin-12 (IL-12). Utilizing Audax’s proprietary AVIKINE® technology, this new candidate is designed to maximize therapeutic effects directly within the tumor microenvironment while minimizing systemic toxicity, a common complication associated with IL-12 therapies. Notably, preclinical studies suggest that DAX-044 may have the potential to achieve a best-in-class position among IL-12 therapeutics.

Research and Development Plans

According to the terms of the agreement, Audax will receive an upfront payment totaling $285 million and will carry DAX-044 into Phase 1 clinical trials expected to initiate in 2027. In the event that Astellas exercises its option, they will take over global development and commercialization efforts while allowing Audax to participate in the financial aspects of the project in their regional markets.

Jai Rautela, CEO of Audax, expressed enthusiasm about the collaboration, stating, "Astellas embodies the pioneering spirit we look for in an ideal partner, particularly for differentiated programs such as DAX-044. This partnership will accelerate the clinical evaluation of DAX-044, which is critical for those afflicted with solid tumors where treatment options remain limited."

The Future of Cancer Treatment

This collaboration between Astellas and Audax is a promising sign in the evolving landscape of cancer therapies. It highlights a commitment to developing innovative solutions that address previously unmet medical needs, ultimately enhancing patient care and outcomes.

As both companies prepare to embark on this venture, stakeholders in the medical and pharmaceutical industries are eager to witness the developments ahead. With ongoing research, potential for additional funding, and a robust clinical pipeline, DAX-044 could represent a significant step forward in the fight against cancer, potentially offering new hope to patients worldwide.

In summary, the collaboration between Astellas and Audax is set to revolutionize the treatment landscape for cancer, particularly in the realm of immuno-oncology. As they work together to realize the potential of DAX-044, the medical community remains optimistic about the future of cancer therapies.